MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism

Melanie A. Paquette, Akari M. Anderson, Jason R. Lewis, Charles K. Meshul, Steven Johnson, S. Paul Berger

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Amantadine and dextromethorphan suppress levodopa (l-DOPA)-induced dyskinesia in Parkinson's disease patients and abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA) rat model. These medications have been hypothesized to exert their therapeutic effects by a noncompetitive N-methyl-. d-aspartate (NMDA) antagonist mechanism, but they also have known serotonin (5-HT) indirect agonist effects that could suppress AIMs. This raised the possibility that NMDA antagonists lacking 5-HTergic effects would not have the anti-dyskinetic action predicted by previous investigators. To test this hypothesis, we investigated MK-801, the most widely-studied NMDA antagonist. We found that chronic low-dose MK-801 (0.1 mg/kg) had no effect on development of AIMs or contraversive rotation. In addition, in l-DOPA-primed rats, low-dose MK-801 (0.1 mg/kg) had no effect on expression of AIMs, contraversive rotation, or sensorimotor function. Conversely, higher doses of MK-801 (0.2-0.3 mg/kg) suppressed expression of AIMs. However, as we show for the first time, anti-dyskinetic doses of MK-801 also suppressed l-DOPA-induced contralateral rotation and impaired sensorimotor function, likely due to non-specific interference of MK-801 with l-DOPA-induced behavior. We conclude that noncompetitive NMDA antagonists are unlikely to suppress dyskinesia clinically without worsening parkinsonism.

Original languageEnglish (US)
Pages (from-to)1002-1008
Number of pages7
JournalNeuropharmacology
Volume58
Issue number7
DOIs
StatePublished - Jun 2010

Fingerprint

Dizocilpine Maleate
Dyskinesias
Parkinsonian Disorders
Levodopa
N-Methylaspartate
Oxidopamine
Dextromethorphan
Amantadine
Serotonin Receptor Agonists
Therapeutic Uses
Aspartic Acid
Parkinson Disease
Serotonin
Research Personnel

Keywords

  • 6-Hydroxydopamine
  • Dyskinesia
  • NMDA
  • Parkinson's disease
  • Rats

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. / Paquette, Melanie A.; Anderson, Akari M.; Lewis, Jason R.; Meshul, Charles K.; Johnson, Steven; Paul Berger, S.

In: Neuropharmacology, Vol. 58, No. 7, 06.2010, p. 1002-1008.

Research output: Contribution to journalArticle

Paquette, Melanie A. ; Anderson, Akari M. ; Lewis, Jason R. ; Meshul, Charles K. ; Johnson, Steven ; Paul Berger, S. / MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. In: Neuropharmacology. 2010 ; Vol. 58, No. 7. pp. 1002-1008.
@article{abfd55e039eb493a9a3480865fbb4ff6,
title = "MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism",
abstract = "Amantadine and dextromethorphan suppress levodopa (l-DOPA)-induced dyskinesia in Parkinson's disease patients and abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA) rat model. These medications have been hypothesized to exert their therapeutic effects by a noncompetitive N-methyl-. d-aspartate (NMDA) antagonist mechanism, but they also have known serotonin (5-HT) indirect agonist effects that could suppress AIMs. This raised the possibility that NMDA antagonists lacking 5-HTergic effects would not have the anti-dyskinetic action predicted by previous investigators. To test this hypothesis, we investigated MK-801, the most widely-studied NMDA antagonist. We found that chronic low-dose MK-801 (0.1 mg/kg) had no effect on development of AIMs or contraversive rotation. In addition, in l-DOPA-primed rats, low-dose MK-801 (0.1 mg/kg) had no effect on expression of AIMs, contraversive rotation, or sensorimotor function. Conversely, higher doses of MK-801 (0.2-0.3 mg/kg) suppressed expression of AIMs. However, as we show for the first time, anti-dyskinetic doses of MK-801 also suppressed l-DOPA-induced contralateral rotation and impaired sensorimotor function, likely due to non-specific interference of MK-801 with l-DOPA-induced behavior. We conclude that noncompetitive NMDA antagonists are unlikely to suppress dyskinesia clinically without worsening parkinsonism.",
keywords = "6-Hydroxydopamine, Dyskinesia, NMDA, Parkinson's disease, Rats",
author = "Paquette, {Melanie A.} and Anderson, {Akari M.} and Lewis, {Jason R.} and Meshul, {Charles K.} and Steven Johnson and {Paul Berger}, S.",
year = "2010",
month = "6",
doi = "10.1016/j.neuropharm.2010.01.003",
language = "English (US)",
volume = "58",
pages = "1002--1008",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism

AU - Paquette, Melanie A.

AU - Anderson, Akari M.

AU - Lewis, Jason R.

AU - Meshul, Charles K.

AU - Johnson, Steven

AU - Paul Berger, S.

PY - 2010/6

Y1 - 2010/6

N2 - Amantadine and dextromethorphan suppress levodopa (l-DOPA)-induced dyskinesia in Parkinson's disease patients and abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA) rat model. These medications have been hypothesized to exert their therapeutic effects by a noncompetitive N-methyl-. d-aspartate (NMDA) antagonist mechanism, but they also have known serotonin (5-HT) indirect agonist effects that could suppress AIMs. This raised the possibility that NMDA antagonists lacking 5-HTergic effects would not have the anti-dyskinetic action predicted by previous investigators. To test this hypothesis, we investigated MK-801, the most widely-studied NMDA antagonist. We found that chronic low-dose MK-801 (0.1 mg/kg) had no effect on development of AIMs or contraversive rotation. In addition, in l-DOPA-primed rats, low-dose MK-801 (0.1 mg/kg) had no effect on expression of AIMs, contraversive rotation, or sensorimotor function. Conversely, higher doses of MK-801 (0.2-0.3 mg/kg) suppressed expression of AIMs. However, as we show for the first time, anti-dyskinetic doses of MK-801 also suppressed l-DOPA-induced contralateral rotation and impaired sensorimotor function, likely due to non-specific interference of MK-801 with l-DOPA-induced behavior. We conclude that noncompetitive NMDA antagonists are unlikely to suppress dyskinesia clinically without worsening parkinsonism.

AB - Amantadine and dextromethorphan suppress levodopa (l-DOPA)-induced dyskinesia in Parkinson's disease patients and abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA) rat model. These medications have been hypothesized to exert their therapeutic effects by a noncompetitive N-methyl-. d-aspartate (NMDA) antagonist mechanism, but they also have known serotonin (5-HT) indirect agonist effects that could suppress AIMs. This raised the possibility that NMDA antagonists lacking 5-HTergic effects would not have the anti-dyskinetic action predicted by previous investigators. To test this hypothesis, we investigated MK-801, the most widely-studied NMDA antagonist. We found that chronic low-dose MK-801 (0.1 mg/kg) had no effect on development of AIMs or contraversive rotation. In addition, in l-DOPA-primed rats, low-dose MK-801 (0.1 mg/kg) had no effect on expression of AIMs, contraversive rotation, or sensorimotor function. Conversely, higher doses of MK-801 (0.2-0.3 mg/kg) suppressed expression of AIMs. However, as we show for the first time, anti-dyskinetic doses of MK-801 also suppressed l-DOPA-induced contralateral rotation and impaired sensorimotor function, likely due to non-specific interference of MK-801 with l-DOPA-induced behavior. We conclude that noncompetitive NMDA antagonists are unlikely to suppress dyskinesia clinically without worsening parkinsonism.

KW - 6-Hydroxydopamine

KW - Dyskinesia

KW - NMDA

KW - Parkinson's disease

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=77950935474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950935474&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2010.01.003

DO - 10.1016/j.neuropharm.2010.01.003

M3 - Article

VL - 58

SP - 1002

EP - 1008

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 7

ER -